Diabetes is a highly prevalent chronic metabolic disease worldwide, with type 2 diabetes accounting for more than 90% of cases. It has long faced clinical challenges including irreversible insulin resistance, high complication rates, and insufficient individualized therapy. During 2025–2026, intensive cutting-edge research has emerged across multiple dimensions of diabetes: basic mechanisms, clinical diagnosis and treatment, drug development, and whole-course management. These advances have broken through the limitations of traditional therapies and provided a new basis for precise prevention and control of diabetes.

I. Frontiers in Basic Scientific Research: New Discoveries in Core Mechanisms Unlocking Novel Intervention Targets and Strategies

(1) New Mechanisms of Islet Function Regulation: Precise Repair via Multi-Molecular Pathways

In January 2026, a landmark study by Li Weida and Gao Shaorong’s team at Tongji University, published in Cell Research, revealed a novel pathogenic mechanism by which zinc accumulation drives the loss of β-cell identity. The study confirmed that zinc overload in pancreatic islets during advanced diabetes triggers the integrated stress response (ISR). Through the zinc–ATF4–ARX regulatory axis, it promotes the transdifferentiation of functional β-cells into α-cells, directly causing insufficient insulin secretion. Using a human embryonic stem cell-derived islet model, this work fills the gap in understanding human β-cell degeneration. It also demonstrates that inhibiting ISR and regulating zinc accumulation effectively preserve β-cell identity and improve glycemic control, offering new targets and intervention strategies for islet function restoration and stem cell transplantation therapy for diabetes.

Reference1

(2) New Breakthroughs in Insulin Resistance Mechanisms: Dual Approaches of Tissue-Specific Regulation and Microbiota Intervention

A team at Zhongshan Hospital, Fudan University, established the world’s first four-subtype classification system for insulin resistance in type 2 diabetes. Multi-omics analysis identified core molecular signatures of liver-derived, muscle-derived, adipose-derived, and multi-organ combined resistance. Targeted interventions improved the glycemic control rate by 42% compared with conventional regimens, ending the “one-size-fits-all” dilemma in anti-insulin resistance therapy.

Similarly, a type 2 diabetes subtyping study based on a large Middle Eastern biobank confirmed significant heterogeneity in diabetes subtypes across ethnic groups. Using combined analysis of clinical phenotypes, metabolic profiles, and molecular markers, the study defined diabetes subtypes unique to Middle Eastern populations, further refining the global precision classification system for diabetes. It provides a critical basis for cross-ethnic and individualized diagnosis and treatment, addressing the underrepresentation of ethnic groups in previous research.

Reference2

(3) Mechanisms of Diabetic Complications: Identification of Multiple Targets Enabling Precise Protection

Diabetic complications are the leading cause of disability and death in patients. Multiple cutting-edge studies in 2026 have clarified the core driving mechanisms of different complications, laying a foundation for targeted intervention:

• Diabetic cardiomyopathy: A team led by Professor Russell Sixin at the First Affiliated Hospital of Chongqing Medical University first demonstrated that isovitexin (ISO) protects against oxidative stress injury in cardiomyocytes by upregulating SIRT3 expression, restoring myocardial function by more than 55% in diabetic mouse models. It represents a potential candidate drug for cardiovascular complication protection.
• Diabetic retinopathy: A collaborative study by Shen Wei, Song Hongyuan, and other institutions, published in PNAS, revealed a systemic mechanism: under high glucose conditions, enhanced glycolysis and elevated histone lactylation in monocytes promote the secretion of exosomal periostin, which stabilizes hypoxia-inducible factor 1α and induces neovascularization. This discovery provides a new target for diabetic retinopathy treatment.

Reference3

• Diabetic nephropathy: A research team at Shanghai Jiao Tong University School of Medicine confirmed that abnormal phosphorylation of the podocyte-specific protein nephrin is a core mechanism of proteinuria. Small-molecule drugs that target and activate this protein reduce urinary protein excretion by more than 40% in patients with diabetic nephropathy.

Reference4

II. Major R&D and Clinical Studies in 2026: Intensive Launch of New Drugs with Promising Pipeline Achievements

(1) New Drugs Approved in 2026: Innovative Targets + Improved Dosage Forms Covering the Full Disease Course

(2) Frontier Clinical-Stage Research: Next-Generation Drugs Target Unmet Clinical Needs

1. Multi-Receptor Agonists: From Dual to Triple Targets for Enhanced Efficacy

LY3437943, a triple GIP/GLP-1/GCGR receptor agonist developed by Eli Lilly, released Phase III clinical data. In patients with advanced type 2 diabetes, it reduced HbA1c by an average of 2.1% and body weight by 15.6%, representing a 30% efficacy improvement over the dual-receptor agonist tirzepatide. It also alleviated hepatic steatosis, offering a new option for diabetic patients with non-alcoholic fatty liver disease.

2. Targeted Drugs for Complications: Precise Intervention to Slow Disease Progression

• Diabetic retinopathy: An intravitreal anti-VEGF/Ang-2 bispecific antibody developed by Kanghong Pharmaceuticals showed in Phase III trials that one injection every 8 weeks achieved an 82% regression rate of retinal neovascularization, with a 25% higher visual improvement rate than single-target drugs.
• Diabetic peripheral neuropathy: PF-06753512, a nerve growth factor (NGF) agonist developed by Pfizer, demonstrated in Phase II trials that it significantly relieves limb numbness and pain with a 78% response rate, alleviating suffering for patients with neuropathy.
• Diabetic cardiomyopathy: Based on Professor Russell Sixin’s research, an enteric-coated formulation of isovitexin has entered Phase I clinical trials. Preliminary data show it reduces myocardial oxidative stress marker MDA by 40% in diabetic patients, with marked cardioprotective effects.

References

1. Ma Q, Xu W, Wang X, et al. Zinc accumulation-induced integrated stress response triggers β-cell identity loss. Cell Res. Published online January 28, 2026. doi:10.1038/s41422-026-01222-y
2. Al-Thani NM, Zaghlool SB, Toor SM, Abou-Samra AB, Suhre K, Albagha OME. Subtyping of type 2 diabetes from a large Middle Eastern biobank: Implications for precision medicine. Mol Metab. 2025;99:102195. doi:10.1016/j.molmet.2025.102195
3. Shen W, Nie Z, Wang M, et al. Monocyte-derived exosomal periostin driven by histone lactylation contributes to retinal neovascularization. Proc Natl Acad Sci U S A. 2025;122(44):e2501704122. doi:10.1073/pnas.2501704122
4. Yasuma T, Fujimoto H, D'Alessandro-Gabazza CN, et al. Microbiota-derived corisin accelerates kidney fibrosis by promoting cellular aging. Nat Commun. 2025;16(1):7591. Published 2025 Aug 25. doi:10.1038/s41467-025-61847-2